Richter E, Epping J, Fuchshofen-Röckel M, Heusler H, Zilly W
Leber Magen Darm. 1980 Oct;10(5):234-40.
Patients with acute hepatitis and patients with compensated or decompensated cirrhosis of the liver have a decreased plasma clearance of hexobarbital. This however could not been demonstrated in patients with intra- or extrahepatic cholestasis and patients with primary biliary cirrhosis of the liver. The plasma clearance of methohexital, - a high clearance drug - is not changed in the same way. Also there is no evidence as yet, that patients with liver disease and without a collateral portal circulation do have an increased bioavailability of oral high clearance drugs.
急性肝炎患者以及代偿性或失代偿性肝硬化患者对己巴比妥的血浆清除率降低。然而，这在肝内或肝外胆汁淤积患者以及原发性胆汁性肝硬化患者中并未得到证实。美索比妥是一种高清除率药物，其血浆清除率并未以同样的方式发生改变。目前也没有证据表明，没有门静脉侧支循环的肝病患者口服高清除率药物的生物利用度会增加。
